Document Detail


Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group.
MedLine Citation:
PMID:  9457926     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the safety and efficacy of recombinant FSH (follitropin beta, Puregon; NV Organon, Oss, the Netherlands) and urinary FSH (urofollitropin, Metrodin; Ares-Serono, Geneva, Switzerland). DESIGN: A prospective, multicenter, assessor-blind, randomized, clinical trial. SETTING: Twelve European infertility clinics. PATIENT(S): One hundred seventy-two women (recombinant FSH: n = 105; urinary FSH: n = 67) with clomiphene citrate-resistant normogonadotropic chronic anovulation (World Health Organization group II). INTERVENTION(S): Eligible subjects were randomized (ratio of recombinant to urinary FSH, 3:2) and treated for a maximum of three cycles. A low-dose step-up regimen was used, with 75 IU of FSH given IM daily for a maximum of 14 days and, if needed, weekly increments of half an ampule given thereafter until the threshold dose for follicular development was achieved. MAIN OUTCOME MEASURE(S): Cumulative ovulation rate after three cycles, total FSH dose, and treatment period needed to achieve ovulation. RESULT(S): The cumulative ovulation rates after three treatment cycles were 95% and 96% for the recombinant and urinary FSH groups, respectively. Overall, ovulation was seen in 155 of 223 treatment cycles (69.5%) in the recombinant FSH group, compared with 92 of 138 treatment cycles (66.7%) in the urinary FSH group. In the first cycle, a statistically significantly lower total dose (750 versus 1,035 IU) and a shorter treatment period (10 versus 13 days) were needed in the recombinant FSH group to reach ovulation. Only one case of ovarian hyperstimulation syndrome led to hospitalization. Two sets of twins (one in each treatment group) and one set of triplets (in the recombinant FSH group) were born. CONCLUSION(S): Recombinant FSH (Puregon) is more efficient than urinary FSH (Metrodin) in inducing follicular development.
Authors:
H J Coelingh Bennink; B C Fauser; H J Out
Related Documents :
21284136 - The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disord...
16645536 - Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal dru...
21206556 - Convergent validity of quality of life interview (qoli) in an indian setting: prelimina...
8533626 - A potential single insertion protocol for quinacrine pellet non-surgical female sterili...
19643926 - Health-related quality of life in ckd patients: correlates and evolution over time.
20446116 - The contribution of fatigue and sleepiness to depression in patients attending the slee...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Fertility and sterility     Volume:  69     ISSN:  0015-0282     ISO Abbreviation:  Fertil. Steril.     Publication Date:  1998 Jan 
Date Detail:
Created Date:  1998-03-04     Completed Date:  1998-03-04     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  0372772     Medline TA:  Fertil Steril     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  19-25     Citation Subset:  IM    
Affiliation:
NV Organon, Oss, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anovulation / drug therapy*,  physiopathology
Chronic Disease
Clomiphene / therapeutic use*
Drug Resistance
Female
Fertility Agents, Female / therapeutic use*
Follicle Stimulating Hormone / therapeutic use*,  urine
Gonadotropins / blood*
Humans
Menotropins / therapeutic use*
Ovulation
Prospective Studies
Recombinant Proteins
Reference Values
Time Factors
Chemical
Reg. No./Substance:
0/Fertility Agents, Female; 0/Gonadotropins; 0/Recombinant Proteins; 61489-71-2/Menotropins; 9002-68-0/Follicle Stimulating Hormone; 911-45-5/Clomiphene

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Association of semen quality and occupational factors: comparison of case-control analysis and analy...
Next Document:  Zygote intrafallopian transfer may improve pregnancy rate in patients with repeated failure of impla...